Miriam Götte Shares Study on Exercise Intensity and Immune Recovery in Pediatric Allo-HSCT
Miriam Götte, Group leader “exercise oncology” at West German Cancer Center Essen, shared a post on Linkedin:
“We published a new study in Pediatric Blood and Cancer:
Effects of Low vs. Moderate-High Intensity Exercise During Pediatric Allo-HSCT conducted by Ronja Beller.
Methods:
- Randomized controlled trial with 22 pediatric patients undergoing allogeneic stem cell transplantation
- Supervised, individualized exercise programs (3-5 sessions/week), comparing moderate-high vs. low intensity
Outcomes: innate immune recovery (NK cells), physical fitness, quality of life, safety
Key Results:
- Both programs were safe and feasible with high adherence rates
- The moderate-high intensity exercise group showed a two-fold higher median count of NK cells at day +30 AND
- A notably higher proportion of patients in the moderate-high exercise group reached an absolute NK cell count of ≥120/µL at day +30 compared to the IG low group (72% vs. 40%). This threshold seems to be associated with event-free survival, reduced transplant-related mortality, and lower relapse rates in pediatric HSCT patients.
- Only the moderate-high group maintained leg strength; low-intensity group declined
- Clinical outcomes (e.g. hospitalization length, GvHD) were similar in both groups and fatigue and QoL worsened in both groups.
Conclusion:
- Moderate-high intensity exercise during pediatric allo-HSCT appears safe and may support faster immune recovery and physical strength.
- Larger studies are needed, but exercise could be a valuable supportive therapy—especially in high-risk settings!
Special thanks to Sabrina B. Bennstein and Carolina Chamorro Viña.”
Title: Effects of a Low Versus Moderate–High Intense Exercise Program on Innate Immune Recovery, Fitness, and Quality of Life During Pediatric Allo-HSCT—The ANIMAL Exploratory Randomized Controlled Trial
Authors: Ronja Beller, Sabrina B. Bennstein, Dirk Reinhardt, Gabriele Gauß, Carolina Chamorra Vina, Helmut Hanenberg, Markus Uhrberg, Miriam Götte
You can read the Full Article on Pediatric Blood and Cancer
More posts featuring Allogeneic hematopoietic stem cell transplantation.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023